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Table 1
Patient characteristics
Characteristics Number or
Median(range)
Number of patients 27
Pre-HSCT nuclear GFR (mL/min/1.73m2)
 Patients with renal abnormalities (n¼12) 97 (55-131)
Mild Renal impairment (GFR<90) 4
Moderate Renal impairment (GFR<60) 2
 Patients without renal abnormalities (n¼15) 124 (71-199)
Mild Renal impairment (GFR<90) 2
Post-HSCT renal complications
 Acute kidney injury (doubling of creatinine) 12
 Mild Renal impairment (GFR<90mL/min) 14
 Moderate Renal impairment (GFR<60mL/min) 10
 Severe Renal impairment requiring temporary RRT 1
Attributable Causes for renal complications
(not mutually exclusive)
 Transplant associated thrombotic microangiopathy 9
 BK hemorrhagic cystitis 11
 Nephrotoxic medications 6
 Hepato-renal syndrome due to VOD 1
Early withdrawal of CSA due to renal impairment 11
Post-HSCT Renal Function
 Recovery to GFR>60mL/min at least
In patients with mild renal impairment post-HSCT 13/14
(GFR<90mL/min)
In patients with moderate renal impairment
post-HSCT
5/10
(GFR<60mL/min)
 Chronic Kidney Disease without dialysis
(GFR 35-40mL/min)
2
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regarding these late effects after newer reduced intensity
conditioning (RIC) regimens without irradiation. Our study
goal was to evaluate late endocrine effects after RIC HSCT in
pediatric and young adult patients.
Methods: An IRB approved retrospective chart review was
performed of 120 children and young adults at our center,
who received a single RIC without radiation for HSCT be-
tween 2004 and 2012 and survived at least 1 year. Analysis
was grouped by age (<2 years and 2 years), and diagnosis
(HLH/XLP, other immune disorders (PID), and metabolic or
genetic disorders). Steroid therapy was deﬁned as glucocor-
ticoids administered either before HSCT or beyond 2 months
following HSCT. Height for age z-score (HAZ) and BMI z-
scores (BMI-Z) were examined separately using linear mixed
effects models.
Results: Subjects age 2-17y with height (n¼103) and weight
(n¼120) data both prior to and at least 1 year following HSCT
were analysed for growth. Themean follow-upwas 3.2 years.
All groups displayed short stature before (HAZ ¼ -1.33) and
after HSCT (HAZ ¼ -1.35) (p¼0.66). After HSCT, younger
children with HLH/XLP grew better (HAZ ¼-3.36 vs -1.35, p¼
0.002), while older subjects had worsening (HAZ ¼-.61 vs
-.99, p¼ 0.004), although all remained short. Overall, subjects
receiving steroid therapy were shorter than untreated pa-
tients (p¼0.02). After HSCT, older subjects with HLH/XLP
became thinner (BMI-Z¼ 1.29 vs. 0.61, p¼0.003), and simi-
larly in metabolic or genetic disorders (BMI-Z¼ 0.56 vs. -0.77,
p<0.001). There was a trend toward increased BMI-Z among
younger children in these same groups. Thyroid function
testing was performed on 77 subjects following HSCT. Eleven
(14%) had evidence of primary hypothyroidism, 5 (7%) had
central hypothyroidism, and 2 (3%) had evidence of primary
hyperthyroidism. Of the 66 subjects with 25-OH vitamin D
levels, 46 (70%) were low (<30 ng/mL). Bone densitometry
by DXA scan was below -1 SD in 16 of 21 evaluable subjects
with an average Z-score of -1.8 SD (0.7 to -4.9 SD) at median
duration after HSCT of 2.2 years.
Conclusions: Despite using RIC, children and young adults
still have signiﬁcant late endocrine effects following trans-
plant. Algorithms for early detection of endocrine late effects
should be implemented for RIC transplant survivors. Further
research is required in order to compare post-transplant
endocrine effects after RIC to those after standard chemo-
therapy protocols.315
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Background: Renal and urological congenital abnormalities
in patients with FA raise concern for renal dysfunction and
may affect their eligibility to undergo HSCT or their post-
transplant course and outcome. Some of these patients (or
their physicians) may opt not to proceed with HSCT due to
concerns of adverse outcome. We describe renal anomalies
and associated dysfunction, and their impact on outcomes in
a cohort of patients with FA undergoing HSCT.
Methods: A retrospective chart review of 27 patients with FA
who underwent HSCT between March 2010 and May 2014.Results: 12 patients had structural renal/urological abnor-
malities at baseline. Median nuclear GFR for these patients
was 97 mL/min/1.73sq.m (range: 55-131) compared to 124
mL/min/1.73sq.m (range: 71-199) in those without renal
anomalies (p¼0.03). Additional patient characteristics and
results are shown in Table 1.
Post-HCT renal complications included acute kidney
injury and decreased renal function measured by Cystatin C
GFR. One patient required renal replacement therapy.
Medication doses were adjusted based on Cyst C GFR for all
patients.
The majority of patients (13/14) with renal impairment
pre-transplant recovered to GFR>60mL/min post-transplant.
2 patients with anomalies and pre-HCT GFR <60 mL/min/
1.73sq.m are long term survivors, albeit with modest chronic
kidney disease (CKD) but without the need for dialysis.
Conclusion: Patients with structural renal abnormalities had
lower but surprisingly clinically acceptable pre-HCT GFR.
Two patients with anomalies and pre-HCT GFR <60, are long
term survivors, showing that patients with renal anomalies/
marginal renal function can consider the option of HCT.
Routine weekly Cystatin C-GFR allows careful and individu-
alized medication dosing leading to improved outcomes.316
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Table 1
Patient demographics
Characteristic Number/Median (range)
Number of patients 7
 Male 4
 Female 3
Age at diagnosis (years) 6.75 (1.3-12.5)
Telomere length <lst centile 7
Genetic Mutation
 TINF 2
 DKC1 1
 TERT 2
 RTEL1 1
 Unknown 1
Indication for HSCT
 Bone Marrow Failure 6
 MDS 1
Pre-HSCTs (in 4 patients)
 Mild decreased DLCO 1
 Mild restrictive disease 1
Table 2
Transplant characteristics
Characteristic Number/Median (range)
Age in years at HCT 7.12 (1.7-13.2)
Donor Source
 MSD 1
 URD 6
Donor HLA matching
 Full match 6
 One antigen mismatch 1
Cell dose - Median TNC ( 108/kg) 8.8 (5.5-10)
Neutrophil engraftment (days) 12 (10-16)
Platelet engraftment (days) 20 (14-35)
Mixed chimerism 0
GVHD
 Acute GVHD 2
-Skin Grade II 1
-Gut Grade III 1
 Chronic GVHD (limited) 1
Viral infection
 CMV 4
 EBV 3
 BK 3
 Adenovirus 1
Overall outcome
 Alive 5
 Dead 2
Cause of death (post HCT day of death)
 IPS 154
 MRSA sepsis 858
TNCeTotal Nucleated Cells, IPSeIdiopathic Pneumonia Syndrome, MRSA-
Methicillin-resistant Staphylococcus aureus.
Table 1
Total number of infections per age group
Age (years) 0-2 2-5 >5
n[78 n[58 n[170 p-value
GPC 16 18 44 0.38
GNR 21 7 31 0.09
Mold 1 0 5 0.54
Yeast 3 4 11 0.72
Viral 42 43 126 0.006
Adeno 12 21 37 0.02
BK 2 6 52 <0.0001
CMV 10 13 42 0.1
EBV 20 19 53 0.61
HHV6 4 7 11 0.25
Respiratory 16 9 41 0.38
Flu 4 0 6 0.27
Metapneumo 4 2 6 0.86
RSV 5 5 18 0.59
Paraﬂu 2 4 10 0.47
Rhino 6 4 11 0.95
Noro 7 5 13 0.88
Parvo 0 0 7 0.07
Rota 2 0 3 0.59
Other 0 0 1 1
GPC- gram positive cocci, GNR- gram negative rod, UTI- urinary tract
infection, CMV- cytomegalovirus, EBV- Epstein-Barr virus, HHV6- human
herpes virus 6, Flu- Inﬂuenza A or B, RSV- respiratory syncytial virus
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marrow failure and/or myelosdysplastic syndrome or leu-
kemia associated with DC. HCT for DC is limited by a high
incidence of treatment-related mortality; related to under-
lying chromosomal instability resulting in sensitivity to
chemotherapy and radiation.We report our experience using
a reduced intensity conditioning (RIC) regimen without ra-
diation for HCT in patients with DC.
Methods: Retrospective chart review was performed with
IRB approval.
Results: 7 patients with DC underwent HSCT using a RIC
regimen consisting of alemtuzumab, ﬂudarabine, and lower
dose melphalan between September 2010 and April 2014.
Patient demographics and disease characteristics are shown
in Table 1.
1 patient with MDS and DC did not receive alemtuzumab
to avoid mixed chimerism. The remaining 6 patients all
received alemtuzumab at age appropriate dosing (on Day -22to -18, or day -14 to 10 or day -6 to -2). All patients received
ﬂudarabine fromdays -8 to -4 (30-40mg/m2/dose). Melphalan
dosewas reduced by 50% to 70mg/m2/dose, to avoid excessive
toxicity related to baseline chemo-sensitivity. GVHD prophy-
laxis consisted of cyclosporine and steroids or MMF. None of
the patients had pre-existing hepatic dysfunction.
All patients engrafted and none developed mixed
chimerism. See Table 2 for additional results. 2 patients
developed acute GVHD, one with grade 2 skin GVHD that
evolved in to limited chronic skin GVHD and the second
patient developed grade 3 gut GVHD in the setting of pre-
existing colitis.
5 patients remain alive and well (100% engrafted) at a
median follow up of 28 months (range 5-47.6).
Conclusion: A RIC regimen containing alemtuzumab, ﬂu-
darabine, and lower dose melphalan (without radiation) re-
sults in durable engraftment rates, acceptable toxicity and
improved overall survival inpatientswithDC undergoing HCT.317
Reduced Incidence of Infections in Very Young Children
Undergoing Allogeneic Hematopoietic Stem Cell
Transplantation
Adam S. Nelson 1, Gregory Wallace 1, Beverly Connelly 2,
Stella M. Davies 1, Michael S. Grimley 1, Sonata Jodele 1,
Lara Danziger-Isakov 2. 1 Bone Marrow Transplantation and
Immune Deﬁciency, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2 Pediatric Infectious Disease, Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
Background: Opportunistic infections signiﬁcantly
contribute to morbidity and mortality after HSCT. We hy-
pothesized that there is a difference in the infection rate
based on age at HSCT.
Methods: We retrospectively examined the medical records
of 307 pediatric allogeneic HSCT recipients between 2008
and 2012 at our institution to include all positive infectious
results (bacterial, viral and fungal). Screening practices were
consistent during the time period.
